Boehringer opens three Phase III trials in lung and NEC cancers
Boehringer Ingelheim has initiated three Phase III trials aimed at extending precision oncology approaches into hard-to-treat lung and neuroendocrine cancers, marking a significant late-stage development step for two of its investigational compounds.
The two DAREON programme trials, DAREON-Lung-1 and DAREON-NEC-1, will evaluate obrixtamig, the company's investigational DLL3/CD3 T-cell engager, in first-line small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC) respectively. A third trial, Beamion LUNG-3, will assess zongertinib as adjuvant monotherapy in patients with stage II-IIIB HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) following complete surgical resection.
The trials in detail
DAREON-Lung-1 is evaluating obrixtamig in combination with atezolizumab and chemotherapy against atezolizumab plus chemotherapy alone as a first-line treatment in extensive-stage SCLC. DAREON-NEC-1 is testing obrixtamig added to the standard carboplatin-etoposide backbone versus standard of care alone in DLL3-positive, unresectable locally advanced or metastatic epNEC.
The DLL3 target is expressed on tumour cells in both SCLC and epNEC while remaining largely absent from healthy tissue, making it an attractive biomarker-informed target for patient selection. EpNEC in particular has seen little therapeutic progress over several decades, and the company says survival outcomes in that setting have been stagnant. Obrixtamig is being developed through a long-term collaboration with Oxford BioTherapeutics, which provided the target identification via its OGAP platform.
Beamion LUNG-3 takes zongertinib into earlier-stage disease. The drug, an irreversible tyrosine kinase inhibitor that selectively blocks HER2 while sparing wild-type EGFR, is already approved in the US, China, Hong Kong and Japan for advanced HER2-mutant NSCLC. Beamion LUNG-3 is designed to test whether adjuvant zongertinib can improve disease-free survival after curative-intent surgery, addressing a meaningful recurrence risk that persists even after complete resection in this biomarker-defined population.
"With the launch of these trials, we are advancing our precision oncology ambitions to move targeted therapies into earlier treatment lines and bring biomarker-informed science into late-stage development," said Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim.
Market and competitive context
Boehringer's move into adjuvant NSCLC with zongertinib places it alongside a growing set of targeted agents seeking to establish a foothold earlier in the treatment pathway. AstraZeneca's osimertinib has set a commercial and clinical benchmark in the adjuvant EGFR-mutant NSCLC setting, and the sector is watching closely to see whether HER2-selective inhibitors can replicate that trajectory in a smaller but underserved patient population.
In the T-cell engager space, several companies are pursuing DLL3-directed approaches in SCLC, though the field remains early relative to more established bispecific platforms in haematological malignancies. Boehringer's Phase I data for obrixtamig, presented at ASCO 2026, have provided a safety and activity signal that supports the Phase III investment. The simultaneous initiation of the epNEC trial is notable given the historical lack of biomarker-stratified trials in that indication.
For investors tracking Boehringer's oncology build-out, these three initiations sit alongside Beamion LUNG-2, the ongoing Phase III first-line advanced NSCLC study of zongertinib, suggesting the company is assembling a multi-line development plan for its HER2 franchise while simultaneously expanding obrixtamig's addressable population across NEC subtypes.